ARTICLES BY BARBARA BERGLUND
-
![Nanotechnology]( "Critical Considerations In Outsourcing Nanotechnology Drugs")
Critical Considerations In Outsourcing Nanotechnology Drugs3/27/2019If the mission statement of nanotechnology is “to perform precise interventions at the cellular or molecular level to improve health and promote quality of life,” then the contract manufacturer might seek a mission statement such as, “to enable novel therapy in a safe, effective way, advancing medical science one medicine at a time.”
-
![What To Do When Your CMO Implements New Technology (That Impacts Your Product)]( "What To Do When Your CMO Implements New Technology (That Impacts Your Product)")
What To Do When Your CMO Implements New Technology (That Impacts Your Product)12/12/2017Innovation and improvement efforts need to consider all aspects of the impact, including quality and regulatory considerations, supply constraints, market constraints, and cost.
Barbara Berglund
Barbara Berglund is COO of CMC Turnkey Solutions, where she applies over 20 years of experience in finished pharmaceutical, API, and medical device manufacturing. In particular, she has direct experience with quality assurance and manufacturing of commercial and clinical trial sterile liquid and lyophilized parenterals, microencapsulated products, intravitreal products, suspensions, and solid dosage forms. She has held strategic leadership positions in quality assurance, quality control, sterile manufacturing, and project management and has a particular interest in technical transfers both of processes and analytical procedures. Berglund has an undergraduate degree in chemistry and postgraduate degrees in chemistry and pharmacological and physiological science. She received her PMI PMP (Project Management Institute Project Management Professional) certification in 2007 and her ASQ CQA (American Society for Quality Certified Quality Auditor) and ASQ CMQ/OE (Certified Manager of Quality/Organizational Excellence) certifications in 2015.